ARTEMIS-003: HS-20093 in Patients With Metastatic Castrate-resistant Prostate Cancer (mCRPC) and Advanced Solid Tumors

NCT06001255 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastasis Castration Resistant Prostate Cancer(mCRPC)

Interventions

DRUG: HS-20093

Sponsor

Hansoh BioMedical R&D Company